Wockhardt’s shares jumped 19.3% to ₹1,473 following the US FDA’s acceptance of its antibiotic drug Zaynich’s New Drug Application. The pharma shares have remained under pressure since hitting a one-year high in July 2025 and have so far lost 22% of their value.